Recombinant activated factor VII safety in trauma patients: Results from the CONTROL trial

Journal of Trauma - Injury, Infection and Critical Care

Volumn 71, Issue 1, 2011, Pages 12-18

  Dutton, Richard P ^a   Parr, Michael ^j   Tortella, Bartholomew J ^k   Champion, Howard R ^e   Bernard, Gordon R ^b   Boffard, Kenneth ^c   Bouillon, Bertil ^d   Croce, Martin A ^f   Dimsits, Jeannett ^l   Holcomb, John B ^h   Leppaniemi, Ari ⁱ   Vincent, Jean Louis ^m   Hauser, Carl J ^g  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d UNIVERSITY OF WITTEN HERDECKE   (Germany)

^e UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^f UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^g BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^h UNIVERSITY OF TEXAS   (United States)

ⁱ UNIVERSITY OF HELSINKI   (Finland)

^j UNIVERSITY OF NEW SOUTH WALES   (Australia)

^k NOVO NORDISK INC   (United States)

^l NOVO NORDISK A S   (Denmark)

^m ERASME HOSPITAL   (Belgium)

more..

Author keywords

Hemorrhage; Recombinant factor VIIa; Safety; Thromboembolic complications; Trauma

Indexed keywords

PLACEBO; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; ARTIFICIAL VENTILATION; BLEEDING; BLOOD CLOTTING DISORDER; BRAIN INFARCTION; BRAIN ISCHEMIA; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG SAFETY; EMBOLISM; HEART INFARCTION; HUMAN; INJURY; INTESTINE INFARCTION; INTESTINE ISCHEMIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MORTALITY; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; PERIPHERAL ISCHEMIA; PHASE 3 CLINICAL TRIAL; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEPSIS; SEPTIC SHOCK; SPLEEN INFARCTION; THROMBOPHLEBITIS; VENOUS THROMBOEMBOLISM;

EUROPE; FACTOR VIIA; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MULTIPLE ORGAN FAILURE; MYOCARDIAL INFARCTION; RECOMBINANT PROTEINS; RESPIRATORY DISTRESS SYNDROME, ADULT; RISK FACTORS; SURVIVAL RATE; THORACIC INJURIES; THROMBOEMBOLISM; TRAUMA SEVERITY INDICES; TREATMENT OUTCOME; UNITED STATES;

EID: 79960390714     PISSN: 00225282     EISSN: 15298809     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Boffard KD, Riou B, Warren B, et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma. 2005;59:8-15.
2. Hauser CJ, Boffard K, Dutton R, et al; for the CONTROL Study Group. Results of the CONTROL trial: efficacy and safety of recombinant activated factor VII in the management of refractory traumatic hemorrhage. J Trauma. 2010;69:489-500.
3. O?Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA. 2006;295:293-298. (Pubitemid 43112957)
4. Thomas GO, Dutton RP, Hemlock B, et al. Thromboembolic complications associated with factor VIIa administration. J Trauma. 2007;62: 564-569. (Pubitemid 46568851)
5. Knudson MM, Ikossi DG, Khaw L, Morabito D, Speetzen LS. Thromboembolism after trauma: an analysis of 1602 episodes from the American College of Surgeons National Trauma Data Bank. Ann Surg. 2004;240:490-496.
6. Geerts WH, Jay RM, Code KI, et al. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med. 1996;335:701-707. (Pubitemid 26287356)
7. Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated Factor VII in randomized clinical trials. N Eng J Med. 2010; 363:1791-1800.
8. EMA Product Information. Available at: http://www.ema.europa.eu/docs/en- GB/document-library/EPAR-Product-Information/human/000074/WC500030873.pdf
9. Dutton R, Hauser C, Boffard K, et al. Scientific and logistical challenges in designing the CONTROL trial: recombinant factor VIIa in severe trauma patients with refractory bleeding. Clin Trials. 2009;6:467-479.
10. Wade CE, Eastridge BJ, Jones JA, et al. Use of recombinant factor VIIa in US military casualties for a five-year period. J Trauma. 2010;69:353-359.
11. Perkins JG, Schreiber MA, Wade CE, Holcomb JB. Early versus late recombinant factor VIIa in combat trauma patients requiring massive transfusion. J Trauma. 2007;62:1095-1101.
12. Spinella PC, Perkins JG, McLaughlin DF, et al. The effect of recombinant activated factor VII on mortality in combat-related casualties with severe trauma and massive transfusion. J Trauma. 2008;64:286-294.
13. McLaughlin D, Wade CE, Champion HR, Salinas J, Holcomb JB. Thromboembolic complications following trauma. Transfusion. 2009;49 Suppl 5:256S-263S.
14. Rajan GP, Zellweger R. Cardiac troponin I as a predictor of arrhythmia and ventricular dysfunction in trauma patients with myocardial contusion. J Trauma. 2004;57:801-808. (Pubitemid 39431201)
15. Ammann P, Fehr T, Minder EI, Günter C, Bertel O. Elevation of troponin I in sepsis and septic shock. Intensive Care Med. 2001;27:965-969. (Pubitemid 32662476)
16. John J, Woodward DB, Wang Y, et al. Troponin-I as a prognosticator of mortality in severe sepsis patients. J Crit Care. 2010;25: 270-275.
17. Adams RC, Hamrick M, Berenguer C, Senkowski C, Ochsner MG. Four years of an aggressive prophylaxis and screening protocol for venous thromboembolism in a large trauma population. J Trauma. 2008;65: 300-306.
18. Nathens AB, McMurray MK, Cuschieri J, et al. The practice of venous thromboembolism prophylaxis in the major trauma patient. J Trauma. 2007;62:557-562. (Pubitemid 46568849)